Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 1093 results for "us fda"

In 5 years, US FDA rejected 13,000 Indian products

BENGALURU: As many as 13,334 products made in India were rejected by the (FDA) between 2010 and 2015, FDA data shows. During the period, it rejected imports of 15,087 Chinese products. According to the ministry of commerce and industry, the ... Times of India, 58 minutes ago

277 images for us fda

The World, 1 week ago
CNN Money, 3 days ago
Pharma Letter, 1 week ago, 1 week ago
Pharma Letter, 2 weeks ago
BioSpace, 3 days ago
MedIndia, 3 weeks ago, 2 weeks ago
Med India, 4 weeks ago
Nasdaq, 4 days ago
Epoch Times

FDA Loophole Allows Possibly Dangerous Chemicals in Food

Don't Ask/Don't Tell Food Additive System Puts Many At Risk Since 1958, the FDA has allowed everyday ingredients in food without requiring a lengthy approval process for them. Food companies and their suppliers have never had to prove, for ...
 Huffington Post3 hours ago FDA Loophole Allows Unlabeled and Possibly Dangerous Chemicals in Food  Epoch Times4 hours ago

Should The FDA Require Animal Testing For Your Lube?

Animal rights group PETA is speaking out against new FDA rules that require personal lubricant companies to conductanimal testing. Were talking about actually putting lubeinto rabbits vaginas—and then killing them. At the center of the debate is ...
 Vocativ7 minutes ago

FDA schedules meeting to review Cartiva's PMA for synthetic cartilage implant: 4 points

Here are four points: 1. The meeting is slated to take place on April 20. 2. The implant is intended for the treatment of osteoarthritis at the base of the big toe. 3. The FDA recently completed a five-day inspection of Cartiva's ...
 Becker's Spine Review43 minutes ago CARTIVA, INC. : Announces Tentative Date of FDA Advisory Panel Review of Cartiva SCI  4 Traders9 hours ago Cartiva, Inc. Announces Tentative Date of FDA Advisory Panel Review of Cartiva SCI  TMC Net9 hours ago Cartiva Announces Tentative Date Of FDA Advisory Panel Review Of Cartiva SCI  BioSpace7 hours ago

Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA

Bristol-Myers Squibb Company BMY announced that the FDA has expanded the use of Daklinza (daclatasvir, 60 mg), in combination with Gilead Sciences Inc.'s GILD Sovaldi (sofosbuvir), for the treatment of patients with chronic hepatitis C (HCV) ...
 Zacks.com1 hour ago

FDA clears Dr. Reddy's betamethasone spray for psoriasis

The FDA clears Promius Pharma's Sernivo (betamethasone dipropionate) Spray, 0.05%, a topical steroid for the treatment of adults with mild-to-moderate plaque psoriasis. The commercial launch will commence next quarter. Promius is the U.S. wholly ...
 Seeking Alpha5 hours ago Promius' Sernivo Spray gets FDA approval to treat moderate plaque psoriasis  Pharmaceutical Technology9 hours ago Dr.Reddy's gets FDA nod for anti-psoriasis spray [Mint, New Delhi]  Bloomberg14 hours ago Dr. Reddy's Says Sernivo Spray 0.05% For Plaque Psoriasis Gets FDA Approval  RTTNews.com16 hours ago
European Pharmaceutical Review

US FDA disapproves Vertex's sNDA for expanded use of CF drug Kalydeco

Vertex Pharmaceuticals Incorporated, a global biotechnology company, announced that it received a Complete Response Letter from the US Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of Kalydeco ...
 PharmaBiz11 hours ago Osprey wins FDA marketing approval  Finance News Network1 day ago Telesta Therapeutics bladder cancer therapeutic faces FDA setback  BiotechnologyFocus.ca2 hours ago FDA approves Bristol Myers Squibb's Daklinza's for expanded use to treat patients with hepatitis C  Pharmaceutical Business Review8 hours ago
Libya News Today

Sarepta says FDA delays decision on muscle-wasting disorder drug

Feb 8 Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder. The FDA has delayed the decision to May 26 from late February, the company said. The drug is ...
 Reuters9 hours ago FDA delays decision on Heron's nausea drug  Reuters3 weeks ago FDA staff unconvinced by Sarepta's muscle wasting drug  Reuters3 weeks ago FDA rejects BioMarin's muscle wasting drug; Sarepta drug in focus  Reuters3 weeks ago

FDA makes sweeping changes for opioids

After receiving pressure from Congress, FDA announced several measures aimed at curbing opioid abuse. The new plan calls for increasing abuse-deterrent formulations of opioid medications and upping access to naloxone and alternative pain treatments.
 Formulary Journal6 hours ago FDA announces new strategy to address opioid abuse  UnitedHealthcare3 days ago FDA announces action plan to combat opioid abuse  DrBicuspid.com3 days ago FDA Announces Large Action Plan in Effort to Reverse the Opioid Epidemic  Monthly Prescribing Reference3 days ago

FDA staff sounds encouraging note on Celltrion's biosim of J&J blockbuster Remicade

Dive Brief: During a meeting at the FDA, regulators responded positively to data for Celltrion'sCT-P13, which is a biosimilar version ofJohnson & Johnson's Remicade (infliximab). Remicade (infliximab) isa monoclonal antibody used to treat ...
 BioPharma Dive7 hours ago AbbVie (ABBV), Johnson & Johnson (JNJ) Fall as FDA Staffers Back Celltrion (068270.KQ)'s Remicade Biosimilar 2/8/2016  ClinicSpace8 hours ago Celltrion's Copy of J&J's Remicade Gets FDA Staff Support  Bloomberg3 days ago FDA staff backs biosimilar to Remicade; J&J and AbbVie fall  Reuters3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less